**Supplementary Table 6. Importance calculated by RF for discriminating HPS and non-HPS patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Scaled importance** | **Variable** | **Scaled importance** |
| HypertensionN | 0.00 | Hb | 29.48 |
| HypertensionY | 0.38 | APTT | 21.49 |
| DiabetesN | 0.59 | PT | 7.58 |
| DiabetesY | 0.43 | Fib | 23.61 |
| SexF | 1.49 | INR | 6.70 |
| SexM | 1.38 | PLT | 43.09 |
| SpO2 | 9.19 | Age | 20.08 |
| TBA | 17.36 | BMI | 16.93 |
| TBIL | 8.15 | VEGF | 13.10 |
| DBIL | 13.92 | VEGFR1 | 53.86 |
| ALB | 16.50 | VEGFR2 | 25.30 |
| ALT | 14.59 | MELD | 15.17 |
| AST | 11.47 | PLGF | 25.64 |
| BUN | 32.00 | sFlt1 | 58.93 |
| Cr | 36.15 | sFlt-1/PLGF | 100.00 |

ALB, albumin; ALT, alanine aminotransferase; APTT, activated coagulation time of whole blood; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; DBIL, direct bilirubin; F, female; Fib, fibrinogen; Hb, hemoglobin; INR, international normalized ratio; M, male; MELD, model of end-stage liver disease; N, no; PLGF, placental growth factor; PLT, platelet; PT, prothrombin time; sFlt-1, soluble vascular endothelial growth factor 1; SpO2, pulse oxygen saturation; TBA, total bile acid; TBIL, total bilirubin; VEGF, vascular endothelial growth factor; VEGFR1, vascular endothelial growth factor receptor 1; VEGFR2, vascular endothelial growth factor receptor 2; Y, yes.